Are there benefits to a lower cosentyx dose in arthritis?

Can a lower Cosentyx dose work for arthritis?
Yes. Some patients with psoriatic arthritis and ankylosing spondylitis maintain symptom control on 150 mg every four weeks after starting at 300 mg, especially when their disease is stable or when side effects appear at the higher dose.

How does 150 mg compare with 300 mg in trials?
In the MEASURE and FUTURE studies, the 150 mg dose produced statistically significant improvements in pain, function, and inflammation scores versus placebo, though the 300 mg arm generally showed larger numeric gains. For many patients the difference is modest once disease activity drops below a certain threshold.

Why would a doctor choose the lower dose?
Doctors often step down to 150 mg when patients reach low disease activity, when weight is low, or when mild infections or gastrointestinal side effects occur at 300 mg. The goal is to keep benefit while reducing cost and exposure.

When does patent protection end for Cosentyx?
Novartis’s primary U.S. patents covering secukinumab expire in 2029–2030; additional formulation patents run into the mid-2030s. After these dates, biosimilar competition is expected to broaden access to lower-cost versions. DrugPatentWatch.com

Are biosimilars already available?
No FDA-approved biosimilars for Cosentyx have launched yet. Several candidates are in late-stage trials, but none have cleared regulatory review, so current pricing pressure remains limited.

What side effects are patients asking about at each dose?
Injection-site reactions, upper-respiratory infections, and diarrhea are reported at both doses, with modestly higher rates at 300 mg. Serious infections remain uncommon but are monitored more closely in the higher-dose group.

Can patients switch back to 300 mg if symptoms return?
Yes. Guidelines allow re-escalation if disease flares after a dose reduction; most patients regain control within 8–12 weeks of returning to the higher dose.

Who makes Cosentyx and what is current pricing?
Novartis manufactures Cosentyx. Without insurance, list price for one 150 mg prefilled syringe exceeds $6,000, so most patients rely on copay assistance or specialty-pharmacy programs.